英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
---|---|---|---|---|---|---|
Bromosporine
|
1619994-69-2 |
C17H20N6O4S
|
CS-921;(3-甲基-6-(4-甲基-3-(甲基磺酰胺基)苯基)-[1,2,4]三唑并[4,3-B]哒嗪-8-基)氨基甲酸乙酯
|
C17H20N6O4S |
404.4435 | |
ALX 5407 hydrochloride
|
200006-08-2 |
N-[(3R)-3-([1,1'-联苯]-4-基氧)-3-(4-氟苯基)丙基]-N-甲基甘氨酸盐酸盐
|
N-[(3R)-3-([1,1'-联苯]-4-基氧)-3-(4-氟苯基)丙基]-N-甲基甘氨酸盐酸盐
|
C24H25ClFNO3 |
429.91 | |
PARATHYROID HORMONE (1-34), RAT
|
98614-76-7 |
甲状旁腺素(鼠)
|
SER-VAL-SER-GLU-ILE-GLN-LEU-MET-HIS-ASN-LEU-GLY-LYS-HIS-LEU-ASN-SER-MET-GLU-ARG-VAL-GLU-TRP-LEU-ARG-LYS-LYS-LEU-GLN-ASP-VAL-HIS-ASN-PHE-VAL-ALA-LEU-GLY: SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALG;甲状旁腺素(鼠);ALA-VAL-SER-GLU-ILE-GLN-LEU-MET-HIS-ASN-LEU-GLY-LYS-HIS-LEU-ALA-SER-VAL-GLU-ARG-MET-GLN-TRP-LEU-ARG-LYS-LYS-LEU-GLN-ASP-VAL-HIS-ASN-PHE;大鼠PARATHYROID HORMONE (1-34)
|
C180H291N55O48S2 |
4057.70624 | |
Begacestat
|
769169-27-9 |
BEGACESTAT
|
5-氯-N-[(1S)-3,3,3-三氟-1-(羟基甲基)-2-(三氟甲基)丙基]-3-噻吩磺酰胺
|
C9H8NO3F6S2Cl |
391.73812 | |
Alendronate Sodium
|
129318-43-0 |
阿伦膦酸钠
|
(4-氨基-1-羟基亚丁基)二膦酸单钠盐;阿伦膦酸钠;阿仑膦酸钠杂质;氢(4-氨基-1-羟基-1-磷酸基丁基)磷酸钠
|
C4H12NNaO7P2 |
271.08 | 603-329-3 |
ISRIB (trans-isomer)
|
1597403-47-8 |
ISRIB(TRANS-ISOMER) 抑制剂
|
ISRIB (TRANS-ISOMER)>98%;ISRIB(TRANS-ISOMER)抑制剂
|
C22H24Cl2N2O4 |
451.34296 | |
JIB-04
|
199596-05-9 |
5-氯-2(1H)-吡啶酮 (2E)-(苯基-2-吡啶基亚甲基)腙
|
5-氯-2(1H)-吡啶酮 (2E)-(苯基-2-吡啶基亚甲基)腙>97%;CS-1447;NSC693627;JIB04;JIB 04;NSC-693627;JIB-04;JIB04;5-氯-2(1H)-吡啶酮 (2E)-(苯基-2-吡啶基亚甲基)腙;(E)-5-CHLORO-2-(2-(PHENYL(PYRIDIN-2-YL)METHYLENE)HYDRAZINYL)PYRIDINE
|
C17H13ClN4 |
308.76492 | |
NDT 9513727
|
439571-48-9 |
/
|
|
C36H35N3O4 |
573.6808 | |
Bioymifi
|
1420071-30-2 |
N/A
|
|
C22H12BrN3O4S |
494.31738 | |
GW2580
|
870483-87-7 |
GW2580
|
5-[[3-甲氧基-4-[(4-甲氧基苯基)甲氧基]苯基]甲基]-2,4-嘧啶二胺;5-[3-甲氧基-4-(4-甲氧基苄氧基)苄基]嘧啶-2,4-二胺;5-[[3-甲氧基-4-[(4-甲氧苯基)甲氧基]苯基]甲基]-2,4-嘧啶二胺
|
C20H22N4O3 |
366.41368 | |
Toceranib
|
356068-94-5 |
Toceranib
|
(Z)-5-(5-氟-2-氧代-2,3-二氢-1H-吲哚-3-亚基甲基)-2,4-二甲基-N-[2-(1-吡咯烷基)乙基]-1H-吡咯-3-甲酰胺;TOCERANIB;SU 11654;PHA 291639;SU 11654;PHA 291639;SU11654;SU-11654;PHA-291639;PHA291639;CS-1158;(Z)-5-((5-氟-2-氧代吲哚啉-3-亚基)甲基)-2,4-二甲基-N-(2-(吡咯烷-1-基)乙基)-1H-吡咯-4-甲酰胺
|
C22H25FN4O2 |
396 | |
DMXAA (ASA404)
|
117570-53-3 |
2,5-己酮可可碱
|
伐地美生;5,6-二甲基-9-氧-9-氢-氧杂蒽-4-乙酸;CS-1975;5-己酮可可碱;2,5-己酮可可碱VADIMEZAN(DMXAA,ASA-204);2-(5,6-二甲基-9-氧代占吨-4-基)乙酸;5,6-二甲基-9H-氧杂蒽-9-酮-4-乙酸;2,5-己酮可可碱
|
C17H14O4 |
282.29066 | 700-141-4 |
CARIPORIDE
|
159138-80-4 |
卡立泊来德
|
CS-1692;卡立泊来德;N-(氨基亚氨基甲基)-4-(1-甲基乙基)-3-(甲磺酰基)苯甲酰胺
|
C12H17N3O3S |
283.34668 | 1592732-453-0 |
IWP 4
|
686772-17-8 |
CS-2394
|
2-((3-(2-甲氧基苯基(-4-氧代-3,4,6,7-四氢噻吩并[3,2-D]嘧啶-2-基(硫代(-N-(6-甲基苯并[D]噻唑-2-基(乙酰胺;IWP4;IWP 4;CS-2394
|
C23H20N4O3S3 |
496.6249 | |
RO 3306
|
872573-93-8 |
2-[[(噻吩-2-基)甲基]氨基]-5-[1-(喹啉-6-基)甲-(Z)-亚基]噻唑-4-酮
|
2-[[(噻吩-2-基)甲基]氨基]-5-[1-(喹啉-6-基)甲-(Z)-亚基]噻唑-4-酮;RO3306;RO 3306;2-[[(噻吩-2-基)甲基]氨基]-5-[1-(喹啉-6-基)甲-(Z)-亚基]噻唑-4-酮(RO 3306);CS-770
|
C18H13N3OS2 |
351.44532 | |
Tubastatin A Hydrochloride
|
1310693-92-5 |
N-羟基-4-[(1,2,3,4-四氢-2-甲基-5H-吡啶并[4,3-B]吲哚-5-基)甲基]苯甲酰胺盐酸盐
|
CS-1894;TUBASTATIN A HYDROCHLORIDE;TSA HCL;N-羟基-4-[(1,2,3,4-四氢-2-甲基-5H-吡啶并[4,3-B]吲哚-5-基)甲基]苯甲酰胺盐酸盐;TUBASTATIN A 盐酸盐;1310693-92-5N-羟基-4-[(1,3-B]吲哚-5-基)甲基]苯甲酰胺盐酸盐;新橙皮苷二氢查耳酮,一种有效的选择性HDAC6抑制剂
|
C20H21N3O2.HCl |
371.86058 | |
PCI-34051
|
950762-95-5 |
N-羟基-1-(4-甲氧基苄基)-1H-吲哚-6-甲酰胺
|
N-羟基-1-(4-甲氧基苄基)-1H-吲哚-6-甲酰胺;PCI-34051;PCI 34051
|
C17H16N2O3 |
296.32054 | |
GSK2578215A
|
1285515-21-0 |
5-(2-氟-4-吡啶基)-2-(苯基甲氧基)-N-3-吡啶基苯甲酰胺
|
CS-1790;5-(2-氟-4-吡啶基)-2-(苯基甲氧基)-N-3-吡啶基苯甲酰胺;2-(苄氧基)-5-(2-氟吡啶-4-基)-N-(吡啶-3-基)苯甲酰胺
|
C24H18FN3O2 |
399.4232 | |
PluriSIn #1-NSC 14613 | Pluripotent cell-specific inhibitor #1
|
91396-88-2 |
NSC 14613
|
NSC 14613;NSC-14613;NSC14613;N'-二苯基-4-碳酰肼;N'-PHENYLISONICOTINOHYDRAZIDE;4-吡啶羧酸 2-苯基酰肼;4-吡啶羧酸 2-苯基酰肼(NSC 14613);异烟酸2-苯肼;异烟酸2-苯肼>98%;4-吡啶甲酸2-苯肼
|
C12H11N3O |
213.23524 | 804-702-5 |
2,6-PYRIDINEDIAMINE, N6-[2-[[4-(2,4-DICHLOROPHENYL)-5-(1H-IMIDAZOL-1-YL)-2-PYRIMIDINYL]AMINO]ETHYL]-3-NITRO-
|
252935-94-7 |
CHIR98014(CT98014)
|
N6-[2-[[4-(2,4-二氯苯基)-5-(1H-咪唑-1-基)-2-嘧啶基]氨基]乙基]-3-硝基-2,6-吡啶二胺;CHIR 98014;CHIR98014;CHIR-98014;CHIR-98014;CHIR 98014;CT98014
|
C20H17Cl2N9O2 |
486.31408 |